Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 2/20 | 0.31 |
| ▸ | HTR2B | P41595 | 2/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | F2RL1 | P55085 | 3/20 | 0.30 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.30 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9232102 | 1.00 | HTR2C (0.31) | HTR2CHTR2BHTR2AF2RL1GPR139 | |
| SCHEMBL9234955 | 0.85 | IDO1 (0.37) | — | |
| SCHEMBL9285532 | 0.85 | IDO1 (0.37) | — | |
| SCHEMBL15853732 | 0.77 | ACHE (0.31) | HTR2A | |
| SCHEMBL9229753 | 0.75 | ESR1 (0.45) | HTR2CHTR2BHTR2ATSHRMAPK1 | |
| SCHEMBL16442476 | 0.74 | ALDH1A1 (0.36) | F2RL1GPR139TSHRMAPK1 | |
| SCHEMBL9229804 | 0.73 | SMN1; SMN2 (0.35) | HTR2B | |
| SCHEMBL18928639 | 0.73 | TSHR (0.39) | TSHRMAPK1 | |
| SCHEMBL9070614 | 0.72 | LMNA (0.35) | HTR2BTSHRKDM4E | |
| SCHEMBL13265101 | 0.72 | MEN1 (0.41) | F2RL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8946266-B2 | Substituted triazole and imidazole derivatives as gamma secretase modulators | Janssen Pharmaceuticals, Inc. (US) | 2015-02-03 | — | — | US | disclosed |
| US-20120135981-A1 | NOVEL SUBSTITUTED TRIAZOLE AND IMIDAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS | CELLZOME LIMITED (GB) | 2012-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120135981-A1 | NOVEL SUBSTITUTED TRIAZOLE AND IMIDAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS | BACE1, BACE2, APH1A | HTR2C 549/4885HTR2B 419/4885HTR2A 526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.